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Summary
Persistent contamination of hospital surfaces and
antimicrobial resistance (AMR) is recognized as
major causes of healthcare-associated infections
(HAI). We recently showed that probiotic-based sani-
tation (PCHS) can stably decrease surface patho-
gens and reduce AMR and HAIs. However, PCHS
action is slow and non-speciﬁc. By contrast, bacte-
riophages have been proposed as a decontamination
method as they can rapidly attack speciﬁc targets,
but their routine application has never been tested.
Here, we analysed the feasibility and effectiveness of
phage addition to PCHS sanitation, aiming to obtain
a rapid and stable abatement of speciﬁc pathogens
in the hospital environment. Staphylococcal contami-
nation in the bathrooms of General Medicine wards
was analysed, being those areas the most contami-
nated and Staphylococci the most prevalent bacteria
in such settings. Results showed that a daily phage
application by nebulization induced a rapid and sig-
niﬁcant decrease in Staphylococcus spp. load on
treated surfaces, up to 97% more than PCHS alone
(P < 0.001), suggesting that such a system might be
considered as a part of prevention and control
strategies, to counteract outbreaks of speciﬁc patho-
gens and prevent associated infections.
Introduction
Persistent contamination of hospital environments by
pathogenic microbes is one of the major causes of so-
called healthcare-associated infections (HAI) (Allegranzi
et al., 2011), which represent a main concern in all west-
ern hospitals. In addition, the frequent antimicrobial
resistance of the persisting pathogens, selected by the
pressure exerted by the massive use of antimicrobials in
hospitals, further threatens the severity of associated
infections, which are often rendered untreatable by con-
ventional drugs (ECDC, 2013, 2015). This causes, in the
EU alone, about 4 million infections per year, which are
directly responsible for about 37 000 deaths each year,
and of an economic loss of approximately € 7 billion,
including direct costs only (ECDC, 2013).
The control of pathogen contamination has been
approached so far by conventional sanitation, based on
the use of chemical-based sanitizers and disinfectants,
including chlorine-derivatives, triclosan, chlorhexidine
and others. Although well-intentioned, this approach has
been proven to be unable to decrease microbial contam-
ination in a stable way, as it is not capable of preventing
recontamination, which occurs continuously due to the
presence of inpatients, medical staff, visiting persons,
etc. Other important limitations include the high environ-
mental impact and their potential contribution to the
selection of antimicrobial resistant (AMR) strains, thus
worsening the AMR concern (Bock et al., 2016; Wand
et al., 2017; Fahimipour et al., 2018). Furthermore,
chemical sanitizers kill microbes indiscriminately; thus,
both the pathogenic and the potentially beneﬁcial normal
microbiota are targeted equally. In the search for ideal
decontamination systems, we investigated the potential
of a probiotic-based system (PCHS, Probiotic Cleaning
Hygiene System), showing that, contrarily to chemical-
based ones, it can decrease in a stable way the
pathogen contamination on hospital surfaces (Vandini
et al., 2014), also leading to reduction in AMR species
(Caselli et al., 2016) and ﬁnally inducing a signiﬁcant
decrease in the risk of acquiring a hospital infection and
in the consequent antimicrobial consumption and costs
(Caselli et al., 2018; Caselli et al., 2019). However,
because such a system is essentially based on
the replacement of pathogens by probiotics through a
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competitive exclusion mechanism, its action is slow and
gradual, and cannot be considered as a rapid mean for
the eradication of speciﬁcally targeted pathogens, but
rather as a preventive and stabilizer system. This type of
action might instead be highly desirable when colonized
and/or infected patients are hospitalized, or in cases of
speciﬁc outbreaks, to reduce the risk of infection for sub-
sequent occupiers of the same rooms. In fact, it is
known that the presence of such patients increases sig-
niﬁcantly the risk of contracting that speciﬁc infection for
patients occupying the same room (Huang et al., 2006;
Drees et al., 2008; Nseir et al., 2011), which is due to
the persistence of those pathogens in the environment.
For this reason, we recently investigated the potential
use of lytic bacteriophages, as they are indicated as an
interesting safe and green technology for bacterial
decontamination, having the characteristic of being
extremely speciﬁc for individual bacterial strains, and
thus potentially usable in a targeted way. Lytic bacterio-
phages are safe for humans, being able to only infect
bacteria and unable to transduce them. In addition, their
action is rapid and they can be applied successfully on
surfaces, as reported for treatment of food or food-pro-
cessing surfaces (Abuladze et al., 2008; Tomat et al.,
2014) and against AMR bacteria (Sulakvelidze, 2005;
Jensen et al., 2015). Although previously used only
against high bacterial densities (Jensen et al., 2015),
and mostly in aqueous solution (Abuladze et al., 2008),
our results showed that they can be successfully used to
rapidly decrease the amount of pathogens commonly
associated with HAIs on different types of surfaces,
including AMR strains (D’Accolti et al., 2018). Interest-
ingly, the potential to use phages in the hospital environ-
ment was recently investigated in intensive care units
(ICU), limited to Acinetobacter infections, reporting a sig-
niﬁcant decrease in Acinetobacter-associated HAIs when
adding a single treatment of ICU rooms with anti-Acine-
tobacter phages to the chemical-based disinfection per-
formed at the patient discharge (Ho et al., 2016). Since
persistent contamination is a general concern in the hos-
pital environment and not only conﬁned to ICU wards,
here we aimed to analyse the feasibility and the effec-
tiveness of a routine phage decontamination in addition
to probiotic-based sanitation.
Towards this aim, based on previous reports by us
and others (Marchaim et al., 2012; Petlin et al., 2014;
Caselli et al., 2016, 2018), we focused on the most
prevalent bacterial contamination in one of the most
contaminated areas in hospitals, that is Staphylococcal
contamination in ward bathrooms. Importantly, Staphylo-
coccus species are directly responsible for the highest
percentage of HAIs (Weiner et al., 2016), accounting for
about 20% of total infections (12% caused by S. aureus
and 8% by coagulase-negative staphylococci); infections
are particularly severe when sustained by drug-resistant
staphylococci, including methicillin-resistant S. aureus
(MRSA), which still represents an important challenge in
Europe (Friedrich, 2019). On the other hand, MSRA
decolonization of the hospital environment has been
reported to have a profound impact on the reduction in
MRSA-associated infections (Edgeworth, 2011). Based
on these observations, the sanitation trial was performed
in ward bathrooms, having the further advantage of
allowing the procedures to be performed without the
patients needing to leave the rooms.
Results
Study design
The study was performed in a private hospital located in
Ferrara (Italy), after approval by the local Ethics Commit-
tee. The trial aimed to analyse the potential effective-
ness and feasibility of a sanitation procedure based on
the use of bacteriophages directed against Staphylo-
cocci, as we previously observed that this type of con-
tamination was prevalent on hospital surfaces (Caselli
et al., 2016, 2018), with a particularly high level in ward
bathrooms. To this purpose, eight rooms of the Internal
Medicine ward were enrolled and randomly included in
the Intervention group (four rooms) or in the Control
group (four rooms). Each room was initially monitored for
Staphylococcal contamination for 1 week (three total
samplings on alternate days), to quantify the Staphylo-
coccal load. Then, the bathrooms of the Intervention
group started receiving sanitation consisting of PCHS
plus bacteriophage application, whereas bathrooms of
the Control group received PCHS alone. Staphylococcal
contamination was monitored for 2 weeks at the follow-
ing times: days 1, 3, 5, 7, 9, 10, 11, 14, 16 and 18
(Fig. 1). The study design thus included an internal con-
trol for each room (comparison between phases in the
same room) and parallel controls between groups (com-
parison between the Intervention and Control groups).
Characterization of the initial Staphylococcal
contamination
Prior to starting the bathroom treatment, Staphylococcal
contamination was quantiﬁed and characterized in all
enrolled rooms and bathrooms for 1 week on alternate
days (three total samplings). Five surface points were
sampled by Rodac plates in duplicate: three in the bath-
room (bathroom ﬂoor, sink and shower plate) and two in
the room (room ﬂoor and bed footboard). Colony-forming
unit (CFU) counts showed a mean level of contamination
corresponding to 3.7 9 104 CFU m2 in the bathroom
area (range 0–84 210 CFU m2) and 1.6 9 104 CFU m2
(range 0–41 684 CFU m2) in the room area, respectively,
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conﬁrming a higher contamination level in the bathroom, as
expected. Species identiﬁcation of the isolated Staphylo-
coccus spp., performed by Maldi-Tof, showed that the
majority of isolates were coagulase-negative Staphylo-
cocci, with < 10% represented by S. aureus. In particular,
we documented four prevalent species, in the order of
abundance: S. epidermidis, S. haemolyticus, S. cohni and
S. simulans. Based on these results, and since the ‘Sta-
phylococcal bacteriophage’ preparation was directed
against S. aureus, prior to its use on ﬁeld we tested the
susceptibility of each Staphylococcus isolate to ‘Staphylo-
coccal bacteriophage’ lysis. Susceptibility tests were per-
formed by spot assays and double-layer plate assays,
including the analyses the most prevalent coagulase-nega-
tive Staphylococcus species detected on surfaces, which
together with S. aureus represented almost the whole
Staphylococcal contamination found on tested surfaces.
S. aureus isolated from surfaces had been already previ-
ously characterized for their antibiotic and phage suscepti-
bility, showing that ‘Staphylococcal bacteriophage’
preparation was able to lyse antibiotic susceptible as well
as multidrug-resistant (MDR) isolates in a superimposable
way (D’Accolti et al., 2018). Both spot and soft agar assay
results (Fig. 2) indicated that ‘Staphylococcal bacterio-
phage’ was able to lyse all the Staphylococcus species
detected on hospital surfaces, although S. simulans was
affected to a lesser extent, suggesting a broad tropism of
such phages towards Staphylococcus genus, and allowing
their use against the coagulase-negative staphylococci
detected most frequently on surfaces.
Phage application and impact on Staphylococcal
contamination
Based on the contamination level measured on hospital
surfaces and in previous studies showing optimal
phage:target ratio on hard surfaces (D’Accolti et al.,
2018), a multiplicity of infection (m.o.i.) 1000:1
was chosen for surface treatment, corresponding
to ≥ 4 9 107 plaque-forming unit (PFU) per m2 and
about 2 9 108 PFU per bathroom (considering a bath-
room ﬂoor surface of 4.5 m2). Surfaces were treated by
nebulization. Preliminary tests were performed to opti-
mize the amount of solution needed, to guarantee a
homogeneous dispersion on bathroom surfaces and a
time of water persistence on surfaces of 10 min, which
in previous studies was shown to guarantee optimal
contact between phages and bacterial targets (D’Accolti
et al., 2018). Based on preliminary test results, nebuliza-
tion was performed for 4 min, using 500 ml of solution.
‘Staphylococcal bacteriophage’ was diluted in ﬁltered
PCHS detergent (previously diluted 1:100 in water)
(D’Accolti et al., 2018), at a ﬁnal concentration of
4 9 108 PFU l1, and 500 ml (2 9 108 PFU) was used
per bathroom. During the nebulization procedure, room
inpatients were asked not to use the bathrooms (10 total
minutes). Afterwards, bathroom was fully available for
patients and staff. Phages were applied daily for 7 days,
then discontinued for 4 days and then re-introduced for
a further 7 days. Staphylococcal contamination was
assessed by CFU count on Rodac plates at days 1, 3,
5, 7, 9, 10, 11, 14, 16 and 18, monitoring ﬁve points in
duplicate at each sampling time: bathroom ﬂoor, sink,
shower plate, room ﬂoor and bed footboard. Results
showed a rapid decrease in Staphylococcus spp. on
surfaces following the addition of phages to PCHS sani-
tation (Fig. 3A). The reduction was already detectable at
day 1 (87%) and was maintained or further increased
throughout the following sampling times, until day 7
(97%). When the phage treatment was discontinued
(days 8–11), the Staphylococcus spp. load on surfaces
gradually increased, although the CFU level remained
lower compared to the original load at T0, which
may also be due to the action of the probiotics. The
re-introduction of anti-Staphylococcus phages was
accompanied by a new, more pronounced, reduction in
Fig. 1. Study design and timeline. Eight rooms of the Internal Medicine ward of the Quisisana Hospital in Ferrara were enrolled in the study and
randomly divided into two groups: Intervention group, having the bathroom sanitized by Probiotic Cleaning Hygiene System (PCHS) plus phages;
and Control group, having the bathroom sanitized by PCHS alone. Phage applications (red arrows) and samplings (blue arrows) are indicated.
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Staphylococcus spp. load on surfaces (days 14, 16 and
18), suggesting that the decrease was actually attributa-
ble to phage action. Measured differences were highly
statistically signiﬁcant (P < 0.001), except for the T11
sampling time.
Interestingly, some reduction in Staphylococcus spp.
CFU was also observed in the rooms whose bathrooms
received the phage treatment in addition to PCHS
(Fig. 3B), although the differences between the Interven-
tion and Control groups were not statistically signiﬁcant.
Consistent with contamination data, the CFU decrease
in Staphylococcus spp. observed on bathroom surfaces
was paralleled by the increase in anti-Staphylococcus
phages on surfaces, as measured by speciﬁc qPCR
(Fig. 4). The phage load was in fact signiﬁcantly higher
at all times tested on surfaces of the bathrooms of the
Fig. 2. Phage susceptibility test of Staphylococcus spp. isolated from hospital surfaces. A. Each coagulase-negative Staphylococcus isolate (in
order of abundance S. epidermidis, S. haemolyticus, S. cohni, S. simulans) was ﬁrst analysed for susceptibility to ‘Staphylococcal bacterio-
phage’ preparation by spot test. B. Both S. aureus and non-aureus isolates were tested by soft agar plate assay for their susceptibility to differ-
ent concentrations of ‘Staphylococcal bacteriophage’ preparation, using 10–104 PFU per spot.
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Intervention group compared to the mock-treated bath-
rooms of the Control group (P < 0.001), including days
9, 10 and 11, when the phage treatment was discontin-
ued, suggesting some persistence of residual active
phages on surfaces.
Notably, some increase in phages was also detectable
in the rooms of the Intervention group compared to Con-
trol rooms (P < 0.05), suggesting that phages were
somehow transported from the bathroom to the adjacent
room area. To ascertain whether the decrease in Sta-
phylococcus spp. was speciﬁc, the microbial population
collected from surfaces was further analysed by a qPCR
microarray detecting Staphylococcus aureus, Staphylo-
coccus epidermidis, Enterococcus faecalis, Enterococ-
cus faecium, Escherichia coli, Klebsiella pneumonia/
Enterobacter, Acinetobacter baumannii, Proteus mir-
abilis, Pseudomonas aeruginosa, Clostridium perfrigens,
Clostridium difﬁcile, Aspergillus fumigatus, Candida albi-
cans, total bacteria (panB) and total mycetes (panM).
The results at T0 conﬁrmed the presence of high
amounts of Staphylococcus spp. (4.1 9 104  2 9 103
genomes m2) and showed the presence of detectable
amounts of E. faecalis (102  7 genomes m2), E. fae-
cium (102  5 genomes m2), K. pneumonia/Enterobac-
ter (1.5 9 103  8 9 102 genomes m2) and uniden-
tiﬁed mycetes (2 9 102  1 9 102 genomes m2). At
T18, analysis results showed a decrease only in Staphy-
lococcus spp. genome copies, with no variations in all
the other analysed microbes (Table 1).
Finally, we analysed the PCHS-Bacillus load on treated
surfaces to assess whether the decrease in Staphylococ-
cus spp. number was eventually due to an increase in
PCHS-Bacillus amount. PCHS cleanser contained a mix of
spores of three Bacillus species, namely B. subtilis,
B. pumilus and B. megaterium, as already reported (Case-
lli et al., 2016, 2018). The analyses were performed by
both conventional CFU count on Rodac plates and by
using a speciﬁc qPCR amplifying spo0A Bacillus gene.
The results obtained by direct CFU counts (Fig. 5) showed
that PCHS-Bacillus amounts were superimposable on sur-
faces of the bathrooms of the Intervention and Control
groups, as well as in room areas, at all times tested, con-
ﬁrming that the decrease in Staphylococcus spp. on sur-
faces was associated with phage application rather than an
increase in probiotic Bacilli. Results obtained by qPCR
conﬁrmed CFU count results (data not shown).
Discussion
A stable and speciﬁc decontamination action would be
highly desirable in a sanitation system, as it would pre-
vent infections associated with the persistence of speci-
ﬁc pathogens on hospital surfaces.
Fig. 3. Staphylococcal contamination in enrolled rooms.
A. Staphylococcus spp. load in enrolled bathrooms. Results are
expressed as mean percentage  SD detected in the Intervention
(PCHS + Phages) and Control (PCHS) groups, referred to the initial
load, measured at T0, representing 100% value. B. Staphylococcus
spp. load in enrolled rooms. Results are expressed as mean per-
centage  SD detected in the Intervention (PCHS + Phages) com-
pared to Control (PCHS) groups, where each control sample time
represents 100% value.
Fig. 4. Anti-Staphylococcus phage load in enrolled rooms. Bacterio-
phage amount on treated surfaces was measured by a speciﬁc
qPCR performed on collected samples. Results are expressed as
mean genome copy number  SD in rooms and bathrooms of the
Intervention (PCHS + Phages) and Control (PCHS) groups.
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The conventional sanitation systems used so far are
not able to prevent recontamination, have a high envi-
ronmental impact and can favour the selection of drug-
resistant strains. By contrast, we recently showed that a
probiotic-based sanitation system (PCHS) can modulate
in a stable way the microbiota of treated hospital sur-
faces, leading to a stable decrease in pathogens (about
80% more than conventional chemical detergents),
accompanied by a stable decrease in AMR species (up
to 3 log), and to a concomitant halving of the risk of con-
tracting a HAI (Caselli et al., 2018).
However, limitations of this system are the long time
needed to get a stable microbiota re-modulation (4–
6 weeks) and the lack of speciﬁcity against individual
targets; both aspects are correlated with the mechanism
of action, which resides essentially in the competitive
antagonism that Bacilli exert on the growth of other
microbes. To overcome these limitations, we hypothe-
sized the use of bacteriophages, based on indications in
the literature and on previous results obtained by us
(D’Accolti et al., 2018). Bacteriophages are in fact char-
acterized by having a very rapid action against speciﬁc
bacteria and have been proved effective for treatment of
food or food-processing surfaces (Greer, 2005; Abuladze
et al., 2008; Tomat et al., 2014), as well as against vari-
ous bacterial targets, including S. aureus and E. coli
strains (Sulakvelidze, 2005; Abuladze et al., 2008; Jamal
et al., 2015; Jensen et al., 2015; D’Accolti et al., 2018).
We and others have reported that bacteriophages can
effectively attack and lyse their target bacteria indepen-
dently of their drug-sensitivity (Sulakvelidze, 2005;
Kvachadze et al., 2011; Jensen et al., 2015; D’Accolti
et al., 2018), which renders phages a valuable tool to
Table 1. Microbial load on bathroom surfaces of the Intervention group.
Microbes
T0 (PCHS)
(genome copy no)
T18 (PCHS + Phages)
(genome copy no)
S. aureus 9 9 102  2 9 102 65  54
S. epidermidis 4.1 9 104  2 9 103 1.2 9 103  9 9 102
E. faecalis 102  7 1.2 9 102  9
E. faecium 102  5 0.9 9 102  11
E. coli ND ND
K. pneumonia/Enterobacter 1.5 9 103  8 9 102 1.8 9 103  9 9 102
A. baumannii ND ND
P. mirabilis ND ND
P. aeruginosa ND ND
C. perfrigens ND ND
C. difﬁcile ND ND
A. fumigatus ND ND
C. albicans ND ND
Total bacteria (panB) 7.2 9 104  8 9 103 6.7 9 104  5 9 103
Total mycetes (panM) 6.5 9 102  3 9 102 6.0 9 102  4 9 102
ND, not detected.
Results are expressed as mean genome copy number  SD per m2, measured on bathroom surfaces of the Intervention group at T = 0 and
T = 18 days.
Fig. 5. Bacillus load in enrolled rooms. The amount of PCHS-
derived Bacilli on sanitized surfaces was assessed by CFU counts
on Rodac plates. A. Bacillus load in bathrooms. B. Bacillus load in
rooms. Results are expressed as mean CFU counts  SD per m2,
detected in the Intervention (PCHS + Phages) and Control (PCHS)
groups.
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counteract MDR species contaminating hospital environ-
ments. Furthermore, we recently observed that phages
can be effective against bacterial amounts comparable
to those detected on hospital surfaces, that they main-
tain their activity when diluted in the PCHS detergent
already used for hospital sanitation, and that a contact
time of 10 min in aqueous solution is sufﬁcient to allow
effective contact between phages and target bacteria
(D’Accolti et al., 2018). Based on these data, we aimed
to assess the feasibility and effectiveness of a routine
phage application added to PCHS sanitation. To this
purpose, we focused on ward bathrooms, as they repre-
sent one of the main contaminated areas in the hospital
environment, and on Staphylococcus spp. contamination,
as it represents the most prevalent type of microbial con-
tamination. Eight rooms, randomly subdivided in two
groups, were enrolled in the study: the Intervention
group had the bathrooms sanitized by PCHS and anti-
Staphylococcus phages (‘Staphylococcal bacteriophage’
by Eliava Foundation), whereas the Control group had
the bathrooms sanitized by PCHS alone. Staphylococcal
contamination of hospital surfaces was quantiﬁed and
characterized prior to the start of phage application, as
phages are speciﬁcally targeted towards one or few spe-
cies belonging to a bacterial genus. The results showed
that the majority of contamination was ascribable to
coagulase-negative staphylococci, with S. aureus repre-
senting < 10% of the total Staphylococci. Therefore, we
tested the ability of ‘Staphylococcal bacteriophage’ to
recognize and lyse the Staphylococcus species preva-
lently found on surfaces. Interestingly, all the four preva-
lent Staphylococcus species isolated from surfaces (in
order of abundance S. epidermidis, S. haemolyticus,
S. cohni and S. simulans) were efﬁciently lysed by ‘Sta-
phylococcal bacteriophage’, showing that these phages
have a broad and somehow unexpected tropism, as was
already suggested in previous reports on Sb-1 staphylo-
coccal bacteriophage (Kvachadze et al., 2011). Phages
were applied by nebulization after suspension in ﬁltered
PCHS detergent, for the minimum time to assure sufﬁ-
cient contact between phages and target bacteria in
aqueous solution (10 min, as determined in previous
studies). This also allowed also minimization of discom-
fort for patients, limiting the time during which the bath-
room was not available, and thus allowing a daily
treatment.
Surface contamination analyses, following phage intro-
duction, showed an evident additional effect of phages in
decontaminating surfaces from target bacteria, with an
up to 97% reduction in the Staphylococci number com-
pared to what was obtained using probiotic-based PCHS
sanitation alone. Notably, phage action was very rapid,
being immediately detectable at T1 (initial day of the
trial) and was maintained for 2 days after discontinuing
the treatment, suggesting that it might be effective even
when applied on alternate days. As expected, the action
was speciﬁcally directed towards target bacteria (Staphy-
lococcus spp.), and no variations were observed for
other contaminating species (Gram-negative bacteria or
mycetes), or in the load of PCHS-derived Bacilli. Inter-
estingly, some effect was also observed in the rooms
having their bathrooms treated with phages, suggesting
that phages were somehow also passively transported to
contiguous areas, likely by persons walking and/or
touching phage-treated surfaces. Of course, since Sta-
phylococci can also be transported from the bathroom to
the room, the diminished bathroom contamination might
have had a positive impact on the level of room contami-
nation as well. In conclusion, collected results suggest
that a biological sanitation including phage usage might
be performed not only for occasional treatment of empty
rooms after patient discharge, as previously reported
(Ho et al., 2016), but also for routine sanitation of speci-
ﬁc areas in the hospital wards. This might help to pre-
vent the persistence of high loads of the most frequent
surface pathogens, thus diminishing the risk of contract-
ing infections associated with those pathogens. Notably,
such a decontamination strategy appears to be economi-
cally sustainable, as PCHS costs are comparable with
those associated with conventional chemical-based sani-
tation, and the additional costs associated with phage
production and application impact minimally on PCHS
costs. Rather, as PCHS alone was proven to be associ-
ated with signiﬁcant cost savings related to the reduction
in HAIs and of consequent antimicrobial therapy (Caselli
et al., 2018, 2019), the use of a more effective sanitation
strategy (probiotic plus phages) might further reduce the
infection rate, allowing additional signiﬁcant cost savings
in terms of HAI management.
Notably, phage biocontrol is becoming increasingly
accepted as an effective and green technology to pre-
vent and/or eliminate contamination by diverse patho-
gens in the food ﬁeld, as well as in water and in
agriculture (Jun et al., 2016; Moye et al., 2018; Svircev
et al., 2018), in substitution of traditional antimicrobial
methods, which kill indiscriminately all bacteria types
and have considerable disadvantages, including large
initial investment potential damage to surfaces and high
environmental impact. Furthermore, the increasing con-
cern of AMR has led to an increasing demand for
methods capable of counteracting resistant microbes
without worsening AMR emergence, especially in the
hospital environment, where such aspects are intrinsi-
cally associated with HAI onset and difﬁcult therapeutic
approaches.
The recently reported effective use of phages in dimin-
ishing the infections associated with the speciﬁc phage
bacterial target in ICU rooms (Ho et al., 2016), together
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with our results showing that such procedure is usable for
daily cleaning purposes, opens the way to future research
aimed at evaluation of the impact of a combined probiotic-
phage strategy on speciﬁc nosocomial infections.
Although we did not observe a reduction in effective-
ness in ‘Staphylococcal bacteriophage’- treated bacteria
on surfaces, one limitation of our study is the lack of
assessment of potential onset of phage resistance in
treated Staphylococci. Previous in vitro reports showed
the appearance of phage resistance with a 1.3 9 108
frequency for S. aureus (Capparelli et al., 2007), sug-
gesting that it may be a quite infrequent event. Gener-
ally, phage resistance was observed in phage therapy
models (Oechslin, 2018), where the density of actively
proliferating bacteria is very high. By contrast, bacterial
density is much lower on hospital surfaces, where bacte-
rial increase is mainly due to recontamination phenom-
ena (continuous spread of pathogens by inpatients and
staff), rather than to proliferation of contaminating spe-
cies, thus rendering even more unlikely the onset of
phage resistance. However, future studies should be
addressed to analyse any potential risk to develop resis-
tance to phages in the pathogens contaminating treated
surfaces.
In conclusion, being that phages are completely safe
for humans, so much so that they are used for therapeu-
tic purposes, we think that such systems might be con-
sidered as a part of prevention and control strategies, to
prevent frequent infections, or as a tool to counteract
outbreaks of speciﬁc pathogens in speciﬁc settings.
Experimental procedures
Setting and ethics statement
The study was performed in the private hospital Qui-
sisana (Ferrara, Italy), after approval by the local Ethics
Committee (December 12, 2016) and authorization of
the Hospital Medical Director (July 13, 2017). The whole
hospital has been routinely sanitized since 2014 by the
probiotic-based PCHS system (Caselli et al., 2016). The
bathrooms of eight rooms of the Internal Medicine ward
were included in the study.
Study design
The effectiveness of two different sanitation methods
was compared by evaluating the level of contamination
of the bathrooms of eight rooms located in the Internal
Medicine ward. The enrolled rooms were all equipped
with an internal bathroom of 4.5 m2 and were randomly
subdivided into two groups: the bathrooms of four rooms
received PCHS sanitation plus phage decontamination
(Intervention group), whereas the bathrooms of the
remaining four rooms continued to receive sanitation by
PCHS alone (Control group). The room surfaces were
sanitized by PCHS alone in both groups. Staphylococcal
contamination was monitored every 2 days until the end
of the trial (23 total days).
Microbiological analyses
Surface Staphylococcal contamination was assessed by
CFU counts on Rodac plates. Five points per room were
sampled, each point in duplicate: bathroom ﬂoor, bathroom
sink, bathroom shower plate, room ﬂoor and room bed
footboard. Rodac plates of 24 cm2 of diameter, containing
Baird-Parker agar medium selective for staphylococci
(Merck Millipore, Billerica, MA USA), were used for sam-
pling as previously described (Caselli et al., 2016, 2018;
D’Accolti et al., 2018). After sampling, plates were immedi-
ately refrigerated and incubated at 37°C for 48 h within 2 h
of sampling. At the end of the incubation time, CFUs were
counted and expressed as CFU m2. A total of 400 sam-
ples were collected and analysed. The same plates were
used also for simultaneous Bacillus spp. enumeration, as
Bacilli can grow efﬁciently on Baird-Parker medium.
Molecular analyses
The same points collected for microbiological analyses
were also sampled by sterile swabs, using a 10 9
10 cm surfaces, as already described (Caselli et al.,
2016, 2018). Swabs were put in sterile tubes containing
0.4 ml of sterile PBS, immediately refrigerated and fro-
zen at -80°C within 2 h. At the moment of analysis, sam-
ples were thawed and vortexed (3 9 30 s), to detach
microbes from the swab. Total DNA was then extracted
from the PBS suspension by a commercial kit (Gene All,
Tema Ricerca, Italy), following the manufacturer’s
instructions.
Three different molecular assays were performed on
extracted DNA: total bacterial quantiﬁcation, PCHS-Bacil-
lus quantiﬁcation and characterization of microbial con-
tamination and anti-Staphylococcus bacteriophage
quantiﬁcation. Total bacterial load and Bacillus quota
were evaluated, respectively, by a panbacterial (panB)
and a Bacillus-speciﬁc (spo0A) quantitative real-time
PCR (qPCR), as described (Caselli et al., 2016, 2018).
Characterization of the microbial contamination was per-
formed on bathroom surfaces only, by a customized
array assessing simultaneously the presence of the fol-
lowing microbes: S. aureus, S. epidermidis, E. faecalis,
E. faecium, E. coli, K. pneumonia/Enterobacter, A. bau-
mannii, P. mirabilis, P. aeruginosa, C. perfrigens, C. dif-
ﬁcile, A, fumigatus and C. albicans (Qiagen, Hilden,
Germany). Bacteriophage load on treated surfaces was
measured by a speciﬁc qPCR designed in the ORF79
(major capsid protein) gene of the Staphylococcus Sb-1
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phage genome (NCBI Ref. Seq. NC_023009.1). Primers,
probe and conditions were as follows: forward primer
SB-1(F) 50-GTG ATA TCT CAC GCC GTC C-30, reverse
primer SB-1(R) 50-TTT GGG TCA GAT ACT GGT GC-30,
probe SB-1(P) 50-FAM-GTC ATG GTA ACG TAG GTC
A-MGB-30; thermal conditions were as follows: 40 cycles,
60°C, using a Quant Studio 5 instrument (Thermo
Fisher, Life Technologies). Prior to use, speciﬁcity of Sb-
1qPCR was checked by amplifying DNA extracted from
bacteriophages targeting different bacterial species,
including E. coli, P. aeruginosa and S. enteritidis. No
positive reaction was detected with any of the phages
other than Sb-1 phage (not shown).
Bacterial isolates
Staphylococci population contaminating tested surfaces
were characterized by cultural isolation of individual Sta-
phylococcus colonies grown on Rodac Baird-Parker agar
plates. Each colony was streaked on a new Baird-Parker
plate and identiﬁed by MALDI-Tof (AccuPRO-ID; Charles
River Lab Europe SaS, Ecully, France). Each isolate was
characterized for susceptibility to ‘Staphylococcal bacterio-
phage’ by spot test and double-layer plate assays. For
spot tests, bacteria in the logarithmic growth phase were
seeded on agar plates, and 10 ll of phage preparation
was added in a single drop at the centre of the seeded
bacteria. Lysis plaques were observed after 24 h of incu-
bation at 37°C. Double-layer plate assays were performed
as previously described (D’Accolti et al., 2018).
Bacteriophages
The concentrated phage product used in this study was
obtained from the ‘Eliava Biopreparations’ Ltd. (Tbilisi,
Georgia) and consisted of a concentrated solution of the
‘Staphylococcal Bacteriophage’ preparation, that is usu-
ally commercially available at the concentration of 107
plaque-forming units (PFUs) per ml. Instead, the concen-
trated phage product produced for this study contained
1010 PFU per ml. It was maintained at 4°C until use and
titred as previously described (D’Accolti et al., 2018).
The ability of ‘Staphylococcal bacteriophage’ product to
recognize and lyse Staphylococci isolated from hospital
surfaces was ﬁrst assessed by spot assays and then by
double-layer plate tests, as previously described, using
10, 102, 103 and 104 PFU per spot (in 10 ll per spot)
(D’Accolti et al., 2018). For phage application on hospital
surfaces, concentrated ‘Staphylococcal bacteriophage’
was diluted in 0.5 lm ﬁltered PCHS detergent at work
dilution (1:100 in water) (D’Accolti et al., 2018), obtaining
a ﬁnal concentration corresponding to 4 9 109 PFU l1.
Such phage preparation is stable for about a week
(D’Accolti et al., 2018).
Sanitation procedures
All enrolled rooms received PCHS sanitation both in the
room and in the bathroom, performed as already described
(Vandini et al., 2014; Caselli et al., 2016), whereas bath-
rooms were treated differently depending on the room
group: Intervention group bathrooms received PCHS sani-
tation and phage treatment, whereas the Control group
bathrooms received PCHS sanitation alone. All sanitation
procedures were performed in the early morning. After opti-
mizing volume and time of application to guarantee homo-
geneous distribution and persistence of an aqueous ﬁlm on
treated surface for 10 min (which was previously shown to
allow an efﬁcient contact between phages and bacterial tar-
gets) (D’Accolti et al., 2018), a total volume of 500 ml of
solution was nebulized in each bathroom by an atomizer.
Patients were asked not to use the bathroom for the time of
application, whereas the bathroom was immediately avail-
able afterwards. Phage application was performed daily for
1 week (days 1–7), then discontinued for 4 days (days 8-
11) and re-introduced for 7 additional days (days 12–18).
Statistical analyses
Statistical analyses were performed using parametric
Student’s t-test and assuming as statistically signiﬁcant a
P value at least < 0.05. Analyses were performed using
the IBM SPSS 23 software (IBM Corporation, New
Orhard Road, Armonk, NY, USA).
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